In AMA guidance, spontaneous reporting of adverse drug or device events is described as which?

• A. Rare and unnecessary
• B. An irreplaceable source of valuable information
• C. Harmful to patient safety
• D. Optional

Answer: (B)

Spontaneous reporting is valued because it serves as an essential, real-world safety signal system. Health professionals and patients voluntarily share adverse events they suspect are linked to a drug or device, capturing information that rarely shows up in premarketing trials due to limited size, duration, or specific patient populations. These reports create early indications of potential safety issues, help identify new risks, and trigger deeper investigations, leading to actions like label changes, warnings, or safety communications. It’s not about being optional or unnecessary; it’s a fundamental, irreplaceable source of information that supports ongoing protection of patients.